Menu

Markets

Research

News

Learn
Paper trading
AI Chat
Get the app WatchlistsPortfoliosAlerts
Sign in

Sunshine Biopharma, Inc. SBFM

Set alert

Price alert · SBFM

All alert types
2.79 USD +0.04 +1.45%

As of Nov 3, 2:16 PM ET

Bid
2.74 × 4
Ask
2.82 × 1
2.67 Day range 2.87
2.58 52-week range 464.00
YTD
-98.87%
1 year
-99.18%
Open
2.70
Prev close
2.75
Mkt cap
2.12M
Vol
38.41K
Avg vol
305.32K
EPS
-189.00
P/E
0.00
Div yield
0.00%
More statistics
Low
2.67
High
2.87
Forward P/E
0.02
Beta
-1.04
Short ratio
0.39
Inst. own
1.84%
Dividend
0.00
Ex-div date
50-d avg
2.80
200-d avg
25.68
1y target
300.00

3M chart

Chart tools
Interval
1m5m15m30m

Events in this range
  • Oct 26, 2026Split: 1 for 20
Signals (8)
NameDateAgo
MACD: Buy SignalOct 23, 20261 week ago
RSI: OversoldOct 9, 20263 weeks ago
RSI: OversoldSep 28, 20261 month ago
RSI: OversoldSep 23, 20261 month ago
MACD: Sell SignalSep 18, 20261 month ago
RSI: OversoldSep 17, 20261 month ago
RSI: OversoldAug 25, 20262 months ago
RSI: OversoldAug 7, 20262 months ago

Financial health

Altman Z-Score

-1.27 Distress zone

Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.

Piotroski F-Score

2 / 9 Weak

Nine pass/fail tests of profitability, leverage and efficiency.

FMP rating

B-3 / 5 overall

  • DCF 3
  • Return on Equity 1
  • Return on Assets 1
  • Debt / Equity 4
  • P/E 1
  • P/B 5

Valuation

P/E -0.9×
FY 2016: -972×FY 2017: -19966×FY 2018: -225×FY 2019: -0.0×FY 2020: -0.5×FY 2021: -0.6×FY 2022: -0.4×FY 2023: -1.5×FY 2024: -0.4×FY 2025: -0.9×
FY 2016 5y median -0.6× FY 2025
P/S 0.1×
FY 2016: 0.0×FY 2017: 0.0×FY 2018: 1088×FY 2019: 76.7×FY 2020: 17.6×FY 2021: 35.8×FY 2022: 2.2×FY 2023: 0.3×FY 2024: 0.1×FY 2025: 0.1×
FY 2016 5y median 0.3× FY 2025
P/B 0.2×
FY 2016: 0.0×FY 2017: -36196×FY 2018: -8724×FY 2019: -2.2×FY 2020: -1.3×FY 2021: 38.7×FY 2022: 0.4×FY 2023: 0.3×FY 2024: 0.1×FY 2025: 0.2×
FY 2016 5y median 0.3× FY 2025
P/FCF -0.9×
FY 2016: 0.0×FY 2017: -37924×FY 2018: -915×FY 2019: -3.3×FY 2020: -1.9×FY 2021: -4.5×FY 2022: -1.8×FY 2023: -0.7×FY 2024: -0.1×FY 2025: -0.9×
FY 2016 5y median -0.9× FY 2025
EV/EBITDA 0.6×
FY 2016: -0.2×FY 2017: -22346×FY 2018: -245×FY 2019: -2.4×FY 2020: -0.8×FY 2021: -0.7×FY 2022: 0.4×FY 2023: 2.4×FY 2024: 1.3×FY 2025: 0.6×
FY 2016 5y median 0.6× FY 2025
EV/Sales -0.1×
FY 2016: 0.0×FY 2017: 0.0×FY 2018: 1090×FY 2019: 109×FY 2020: 30.5×FY 2021: 35.2×FY 2022: -2.6×FY 2023: -0.4×FY 2024: -0.2×FY 2025: -0.1×
FY 2016 5y median -0.2× FY 2025
FCF Yield -107.7%
FY 2016: 0.0%FY 2017: -0.0%FY 2018: -0.1%FY 2019: -30.7%FY 2020: -52.4%FY 2021: -22.4%FY 2022: -57.1%FY 2023: -144.4%FY 2024: -705.4%FY 2025: -107.7%
FY 2016 5y median -107.7% FY 2025

Profitability

Gross Margin 32.8%
FY 2016: 0.0%FY 2017: 0.0%FY 2018: 12.5%FY 2019: 47.7%FY 2020: 63.8%FY 2021: 48.4%FY 2022: 39.0%FY 2023: 34.6%FY 2024: 30.6%FY 2025: 32.8%
FY 2016 5y median 34.6% FY 2025
Operating Margin -12.3%
FY 2016: 0.0%FY 2017: 0.0%FY 2018: -260.9%FY 2019: -3037.9%FY 2020: -807.8%FY 2021: -1068.2%FY 2022: -199.6%FY 2023: -19.9%FY 2024: -16.7%FY 2025: -12.3%
FY 2016 5y median -19.9% FY 2025
Net Margin -16.5%
FY 2016: 0.0%FY 2017: 0.0%FY 2018: -482.1%FY 2019: -7860.9%FY 2020: -3898.7%FY 2021: -5444.4%FY 2022: -615.4%FY 2023: -18.7%FY 2024: -14.7%FY 2025: -16.5%
FY 2016 5y median -18.7% FY 2025
ROE -25.9%
FY 2016: 1667.5%FY 2017: 181.4%FY 2018: 3867.3%FY 2019: 225.8%FY 2020: 291.6%FY 2021: -5875.6%FY 2022: -123.7%FY 2023: -21.2%FY 2024: -21.8%FY 2025: -25.9%
FY 2016 5y median -25.9% FY 2025
ROIC -18.8%
FY 2016: -3641.6%FY 2017: -374.4%FY 2018: -130.1%FY 2019: 3237.8%FY 2020: -60.2%FY 2021: -115.6%FY 2022: -38.1%FY 2023: -21.8%FY 2024: -22.7%FY 2025: -18.8%
FY 2016 5y median -22.7% FY 2025
ROA -19.9%
FY 2016: -5429.3%FY 2017: -404.0%FY 2018: -188.1%FY 2019: -1691.7%FY 2020: -266.3%FY 2021: -564.6%FY 2022: -90.5%FY 2023: -16.5%FY 2024: -16.8%FY 2025: -19.9%
FY 2016 5y median -19.9% FY 2025

Growth (YoY)

Revenue 4.1%
FY 2016: -100.0%FY 2017: 0.0%FY 2018: 0.0%FY 2019: -95.3%FY 2020: 238.1%FY 2021: 219.9%FY 2022: 1802.4%FY 2023: 454.4%FY 2024: 44.7%FY 2025: 4.1%
FY 2016 FY 2025
Operating Income 22.9%
FY 2016: -27.3%FY 2017: 13.7%FY 2018: -36.1%FY 2019: 45.0%FY 2020: 10.1%FY 2021: -323.0%FY 2022: -255.5%FY 2023: 44.8%FY 2024: -21.5%FY 2025: 22.9%
FY 2016 FY 2025
EPS (diluted) 80.3%
FY 2016: 100.0%FY 2017: 85.5%FY 2018: -495.6%FY 2019: -13186.6%FY 2020: 83.0%FY 2021: -196.1%FY 2022: 63.0%FY 2023: 90.0%FY 2024: 97.9%FY 2025: 80.3%
FY 2016 FY 2025
Free Cash Flow 62.9%
FY 2016: 78.7%FY 2017: -72.3%FY 2018: 2.8%FY 2019: 6.6%FY 2020: -32.6%FY 2021: -177.8%FY 2022: -203.6%FY 2023: -72.2%FY 2024: -55.3%FY 2025: 62.9%
FY 2016 FY 2025

Financial Health

Current Ratio 4.2×
FY 2016: 0.2×FY 2017: 0.2×FY 2018: 0.2×FY 2019: 0.1×FY 2020: 1.0×FY 2021: 24.1×FY 2022: 3.9×FY 2023: 4.5×FY 2024: 4.1×FY 2025: 4.2×
FY 2016 5y median 4.2× FY 2025
Quick Ratio 2.1×
FY 2016: 0.2×FY 2017: 0.2×FY 2018: 0.2×FY 2019: 0.1×FY 2020: 1.0×FY 2021: 22.9×FY 2022: 3.5×FY 2023: 3.5×FY 2024: 2.3×FY 2025: 2.1×
FY 2016 5y median 3.5× FY 2025
Debt / Equity 0.0×
FY 2016: -1.1×FY 2017: -1.4×FY 2018: -17.1×FY 2019: -1.0×FY 2020: -2.0×FY 2021: 9.0×FY 2022: 0.0×FY 2023: 0.0×FY 2024: 0.0×FY 2025: 0.0×
FY 2016 5y median 0.0× FY 2025
Net Debt / EBITDA 1.5×
FY 2016: -0.2×FY 2017: -0.7×FY 2018: -0.4×FY 2019: -0.7×FY 2020: -0.4×FY 2021: 0.0×FY 2022: 0.8×FY 2023: 4.1×FY 2024: 1.7×FY 2025: 1.5×
FY 2016 5y median 1.5× FY 2025
Interest Coverage 0.0×
FY 2016: -28.6×FY 2017: -8.2×FY 2018: -7.3×FY 2019: -5.5×FY 2020: -3.4×FY 2021: -7.4×FY 2022: -220×FY 2023: -34.9×FY 2024: -662×FY 2025: 0.0×
FY 2016 5y median -34.9× FY 2025

Dividends

Dividend Yield 0.0%
FY 2016: 0.0%FY 2017: 0.0%FY 2018: 0.0%FY 2019: 0.0%FY 2020: 0.0%FY 2021: 0.0%FY 2022: 0.0%FY 2023: 0.0%FY 2024: 0.0%FY 2025: 0.0%
FY 2016 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2016: 0.0%FY 2017: 0.0%FY 2018: 0.0%FY 2019: 0.0%FY 2020: 0.0%FY 2021: 0.0%FY 2022: 0.0%FY 2023: 0.0%FY 2024: 0.0%FY 2025: 0.0%
FY 2016 5y median 0.0% FY 2025

Annual · latest fiscal year ends 2025-12-31